Zimbabwe has rejected a significant US health deal valued at $367m (£272m) spanning five years due to the United States' demand for sensitive biological samples.
This rejection was revealed following a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson has since clarified that the United States was requesting genetic material for research and commercial purposes but was not willing to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued talks to reach a agreement agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Background
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court halted a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
Based on reports, Sixteen nations in Africa have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would supply the raw materials for medical research with no assurance that the end products would be available to our population if a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were undermining systems previously established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation could be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts said it recognised the government's concerns, but recommended that negotiations should continue since a large portion of the country's HIV programmes relied on international support.
"In cases where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group commented.
The halted deal highlights the ongoing debate between receiving vital foreign assistance and protecting local interests in an ever more data-driven world.